Target intelligence / Profile preview

Imidazoline I1 receptor (I1 receptor)

Target
I1 receptor
Molecular classification
Receptor, G protein-coupled receptor (putative), Neurocytokine receptor family (proposed)
01

Overview

The Imidazoline I1 receptor is a cell-surface binding site primarily located on the plasma membrane of neurons within the rostral ventrolateral medulla, as well as in other tissues such as adrenal medulla, renal epithelium, pancreatic islets, platelets, and prostate. It plays a key role in inhibiting sympathetic nervous system activity to lower blood pressure. The I1-imidazoline receptor is distinct from alpha2-adrenoceptors but shares some pharmacological overlap; it mediates the antihypertensive actions of drugs like moxonidine and rilmenidine by decreasing sympathetic tone centrally. Activation leads to signal transduction involving diacylglycerol production via phosphatidylcholine-selective phospholipase C. Beyond its established role in cardiovascular regulation—especially hypertension—the I1-imidazoline receptor may also influence metabolic processes such as insulin secretion and glucose tolerance. Its molecular identity has been linked with IRAS/Nischarin proteins but remains incompletely defined at the gene/protein level. The target continues to be explored for therapeutic applications beyond hypertension due to its involvement in broader physiological processes including inflammation, neuroprotection, cell proliferation, and possibly psychiatric conditions.[1][2][3][4][5][6]

Other names
I1-imidazoline receptorI1 binding siteImidazoline receptor subtype 1
02

Mechanism of action

Agonists lower blood pressure by inhibiting central sympathetic outflow through activation of the I1-imidazoline receptor in the rostral ventrolateral medulla, leading to vasodilation and reduced peripheral vascular resistance[2][4][5].

03

Biological functions

Inhibition of sympathetic nervous system activityCentral regulation of blood pressureSignal transduction via diacylglycerol and phospholipase C pathwaysModulation of catecholamine synthesis enzymes[1][2][5][6]
04

Disease associations

Cardiovascular disease (notably hypertension)Metabolic syndrome/insulin resistance[2][6]Potential roles in inflammation, neuroprotection, and psychiatric disorders[3]
05

Safety considerations

Hypotension from excessive sympathoinhibition[7]Potential for bradycardia or other cardiovascular effects due to central action on autonomic tone[7]Generally improved side effect profile compared to alpha2-adrenoceptor agonists; less sedation and no reported withdrawal phenomenon with moxonidine/rilmenidine[7]
06

Interacting drugs

Moxonidine (agonist)[2][6][7]

3 more in the full profile.

Beyond the preview

Go deeper on Imidazoline I1 receptor (I1 receptor).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imidazoline I1 receptor (I1 receptor).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call